TY - JOUR
T1 - The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma
AU - Barrington, Sally F.
AU - Trotman, Judith
N1 - Funding Information:
SFB acknowledges support from the National Institute for Health Research and Social Care (NIHR; RP-2–16–07–001). King's College London and University College London Comprehensive Cancer Imaging Centre is funded by Cancer Research UK and Engineering and Physical Sciences Research Council in association with the Medical Research Council and the Department of Health and Social Care (England). This work was also supported by the Wellcome and Engineering and Physical Sciences Research Council Centre for Medical Engineering at King's College London [WT 203148/Z/16/Z]. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Funding Information:
SFB reports research grants from National Institute for Health Research and Social Care, during the study; and grants from Bristol Myers Squibb, Pfizer, and Amgen, outside the submitted work; and personal fees from Takeda, outside the submitted work. JT reports research grants from Beigene, Roche, Takeda, Celgene, Janssen and PCYC, outside the submitted work.
Publisher Copyright:
© 2021 Elsevier Ltd
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - This Review focuses on the use of 18F-fluorodeoxyglucose (18F-FDG) PET in the assessment of diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma. PET is important for staging and prognostication with stage migration compared with CT. Better outcomes for patients with early stage diffuse large B-cell lymphoma and follicular lymphoma suggests better delineation of disease has translated to improved outcomes in such patients beyond simple stage migration. The aim of treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma is potential cure, during which PET is mainly used to assess remission. Interim PET can assess chemosensitivity in these lymphomas, but it does not predict treatment success sufficiently well to enable treatment modification, particularly in the absence of more effective therapies for patients who remain PET-positive on interim scanning. In follicular lymphoma, traditionally viewed as an incurable lymphoma, the aim of treatment is to control disease for several years, while maintaining quality of life. PET can predict prognosis for patients with follicular lymphoma with high tumour burden at the end of induction chemotherapy, and it is being evaluated as a platform for response-adapted treatment of follicular lymphoma.
AB - This Review focuses on the use of 18F-fluorodeoxyglucose (18F-FDG) PET in the assessment of diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma. PET is important for staging and prognostication with stage migration compared with CT. Better outcomes for patients with early stage diffuse large B-cell lymphoma and follicular lymphoma suggests better delineation of disease has translated to improved outcomes in such patients beyond simple stage migration. The aim of treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma is potential cure, during which PET is mainly used to assess remission. Interim PET can assess chemosensitivity in these lymphomas, but it does not predict treatment success sufficiently well to enable treatment modification, particularly in the absence of more effective therapies for patients who remain PET-positive on interim scanning. In follicular lymphoma, traditionally viewed as an incurable lymphoma, the aim of treatment is to control disease for several years, while maintaining quality of life. PET can predict prognosis for patients with follicular lymphoma with high tumour burden at the end of induction chemotherapy, and it is being evaluated as a platform for response-adapted treatment of follicular lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=85098869316&partnerID=8YFLogxK
U2 - 10.1016/S2352-3026(20)30365-3
DO - 10.1016/S2352-3026(20)30365-3
M3 - Review article
C2 - 33357487
AN - SCOPUS:85098869316
SN - 2352-3026
VL - 8
SP - e80-e93
JO - The Lancet Haematology
JF - The Lancet Haematology
IS - 1
ER -